VTRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Viatris Inc. (VTRS) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has some positive technical indicators and a bullish sentiment from analysts, the lack of recent AI Stock Picker signals, weak financial performance in the latest quarter, and hedge fund selling trends suggest a cautious approach. The investor may consider holding off for now and reassessing after the Q1 2026 financial results on May 7, 2026.
The technical indicators show a bullish trend with MACD positively expanding, RSI in the neutral zone at 68.813, and moving averages aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading near resistance levels (R1: 13.933, R2: 14.145), indicating limited immediate upside potential.
Analysts have raised price targets recently, with Barclays, UBS, and JPMorgan showing confidence in the stock's potential.
Viatris is set to present four studies at the ASCRS Annual Meeting, which could generate positive sentiment.
The company's pipeline and cost-saving initiatives are viewed positively by analysts.
Hedge funds are selling the stock, with a significant 247.32% increase in selling activity last quarter.
The latest financials show a drop in net income (-34.15% YoY) and EPS (-30.23% YoY), indicating weak profitability.
The stock has an 80% chance of declining in the short term based on candlestick pattern analysis.
In Q4 2025, Viatris reported a 4.97% YoY revenue increase to $3.7 billion. However, net income dropped significantly by 34.15% YoY to -$340.1 million, and EPS fell by 30.23% YoY to -0.3. Gross margin improved slightly to 40.25%, up 1.8% YoY, but overall profitability remains a concern.
Analysts are generally positive on Viatris, with recent upgrades and price target increases. Barclays raised its target to $17, UBS to $20, and JPMorgan to $16. Analysts highlight the company's cost-saving initiatives, pipeline growth, and potential for multiple expansion, but some remain cautious due to the macro environment and lower EBITDA growth outlook.
